BCR-ABL1 kinase: hunting an elusive target with new weapons
- PMID: 22118668
- PMCID: PMC3228864
- DOI: 10.1016/j.chembiol.2011.11.001
BCR-ABL1 kinase: hunting an elusive target with new weapons
Abstract
Tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib interfere with ATP-binding pocket to inhibit BCR-ABL1 kinase. A recent report in Cell by Grebien et al. paves the way for a new approach to target BCR-ABL1 kinase by interfering with its SH2-kinase domain interface.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Figures
Comment on
-
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.Cell. 2011 Oct 14;147(2):306-19. doi: 10.1016/j.cell.2011.08.046. Cell. 2011. PMID: 22000011 Free PMC article.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
